Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geissler

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Bioorganic & Medicinal Chemistry Letters|August 31, 2015
Development of a novel tricyclic class of potent and selective FIXa inhibitorsDongfang Meng, Patrick Andre, Thomas J Bateman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Zeitschrift Fur Gastroenterologie|December 17, 2013
[S3-guideline exocrine pancreatic cancer]T Seufferlein, M Porzner, T Becker, et al.
Zeitschrift Fur Gastroenterologie|April 9, 2011
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]M Moehler, S-E Al-Batran, T Andus, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Bioorganic & Medicinal Chemistry Letters|August 31, 2015
Development of a novel tricyclic class of potent and selective FIXa inhibitorsDongfang Meng, Patrick Andre, Thomas J Bateman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Zeitschrift Fur Gastroenterologie|December 17, 2013
[S3-guideline exocrine pancreatic cancer]T Seufferlein, M Porzner, T Becker, et al.
Zeitschrift Fur Gastroenterologie|April 9, 2011
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]M Moehler, S-E Al-Batran, T Andus, et al.
Pageof 13